UCB banks on Georgia for $2bn biologics manufacturing facility
UCB has chosen Georgia as the home for its new biologics manufacturing facility, cementing its legacy in the state and …
Post
-
-
Improving early detection and treatment of liver cancer
Outcomes for liver cancer patients are highly stage dependent. Interventions designed to be curative, such as minimally invasive ablation, tumour …
-
MSD spends $6.7bn to buy Terns Pharmaceuticals in cancer pipeline reinforcement
MSD will buy cancer specialist Terns Pharmaceuticals in a deal worth $6.7bn, as the drugmaker continues its string of multibillion-dollar …
-
Researchers become scientific tastemakers by handing more R&D to autonomous labs
Pharmaceutical R&D is falling increasingly to artificial intelligence (AI)-guided autonomous laboratories, and the people behind them say the role of …
-
Viz.ai and Alnylam to advance earlier identification of cardiac amyloidosis
Viz.ai has entered a collaboration with Alnylam to advance earlier identification and streamline diagnosis for cardiac amyloidosis, an underdiagnosed cause …
-
Viz.ai and Alnylam to advance earlier identification of cardiac amyloidosis
Viz.ai has entered a collaboration with Alnylam to advance earlier identification and streamline diagnosis for cardiac amyloidosis, an underdiagnosed cause …
-
MSD and Quotient collaborate on IBD drug targets
Merck & Co (MSD) has signed a multi-year research collaboration with Quotient Therapeutics to discover new drug targets for inflammatory …
-
Gilead doubles down on cell therapy: Inside the $7.8bn Arcellx acquisition
On 23 February, Gilead Sciences announced its $7.8bn acquisition of Arcellx, primarily to secure rights to anitocabtagene autoleucel (anito-cel), an …
-
Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout
Gilead Sciences is set to acquire Ouro Medicines for $2.2bn, marking the company’s first move into the T-cell engager (TCE) …
-
Monash University and ClinChoice partner on new therapies development
Australia-based Monash University and ClinChoice have announced a strategic partnership to accelerate clinical development of new therapies. This collaboration is also …
-
Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody
Sanofi has signed an exclusive global licence agreement with Kali Therapeutics for KT501, a new tri-specific antibody for B cell-mediated …
-
Clinical trials: Are data managers ready for AI in EDC?
AI in clinical trials has the potential to offer faster insights, greater efficiency, and improved data quality. Nowhere is this …
-
Earendil Labs lands $787m to fund biologics development push
Earendil Labs has secured $787m to drive the expansion of its artificial intelligence (AI)-powered drug discovery platform, which has already …
-
ImmunityBio receives Macau approval for Anktiva combo therapy
ImmunityBio has received approval from the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region, China, for Anktiva (nogapendekin …
-
BMS secures FDA and EC approvals for Opdivo in Hodgkin Lymphoma
Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) has received approvals for two new indications in classical Hodgkin Lymphoma (cHL) from the …
